Astrazeneca invests $2bn in cancer drug tie-up Markets Astrazeneca has invested $2bn in US pharmaceutical firm Summit Therapeutics as part of a blockbuster cancer research tie-up. The FTSE 100 drugs giant has agreed to buy 109,000 shares in Nasdaq-listed Summit for $18.36 per share as part of the deal. Shares in Astrazeneca jumped by 1.4 per cent to 12,664p in early trading. The tie-up [...]
Patent cliff fuels Novartis’ $1.5bn swoop for London biotech Healthcare Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global drugmakers continue deploying billions into promising biotech firms ahead of an estimated $450bn wave of patent expiries over the next decade. The deal will see Novartis pay $1.1bn upfront, with a further $400m tied to development [...]
Astrazeneca chief blasts Europe for ‘putting citizens’ health at risk’ healthcare Europe is putting its “ability to protect the health of its own people at risk” by not investing enough, the chief executive of FTSE 100 giant Astrazeneca has warned. Pascal Soriot added that the continent is “falling behind” in attracting R&D and manufacturing investment and needs to “invest more in what really matters to it”. [...]
GSK shares rise after £1.7bn Zantac settlement October 10, 2024 GSK shares have spiked today after the pharmaceutical giant agreed to pay as much as $2.2bn (£1.68bn) to settle lawsuits alleging one of its heartburn drugs had caused cancer. The discontinued version of the drug, Zantac, had triggered 80,000 lawsuits from 10 different law firms in the US and has hung over the FTSE 100 [...]
Meet the founder searching for the ‘holy grail’ of cancer treatment October 8, 2024 Jennifer Sieg speaks with Hilmar Warenius about how his discovery of a new type of cancer treatment could be well on its way to revolutionising the pharmaceutical industry
Astrazeneca boosts cardiovascular pipeline with licensing deal October 7, 2024 Astrazeneca has struck a licensing agreement worth up to $2bn (£1.5bn) with China’s CPSC Pharmaceutical Group to develop a new cardiovascular drug, the company announced on Monday. The Anglo-Swedish pharmaceutical giant will pay $100m (£76.5) upfront, with additional milestone payments of up to $1.9bn (£1.4bn), to licence a preclinical small molecule aimed at treating dyslipidemia. [...]
Astrazeneca drags down the FTSE 100 following mixed cancer trial results September 10, 2024 Shares in Astrazenca and Daiichi Sankyo nose dived today after the pair revealed mixed results in their lung cancer drug's late-stage trial.
British Patient Capital invests £90m London biotech company July 8, 2024 British Patient Capital recently also invested £10m into biotech firm Curve Therapeutics to support its cancer drug discovery technology.
Based in an old Bermondsey biscuit factory, this London cancer drug firm just raised millions May 21, 2024 Founded in 2012 by a PhD student, Labgenius uses technology to create more effective and safer antibodies for cancer treatment.
US regulator accepts GSK’s application to expand treatment of cancer drug April 24, 2024 The treatment, Jemperli, will now be classed as being able to help all adult patients with primary advanced or recurrent endometrial cancer. It is used alongside chemotherapy.